<PAGE>
================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. 1)*
ISIS PHARMACEUTICALS, INC.
-------------------------------------------------------
(Name of Issuer)
Common Stock, Par Value $.001 per share
-------------------------------------------------------
(Title of Class of Securities)
464330109
-------------------------------------------------------
(CUSIP Number)
December 31, 1999
-------------------------------------------------------
(Date of Event Which Requires Filing of This Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
|X| Rule 13d-1(b)
| | Rule 13d-1(c)
| | Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which would
alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 ("Act") or otherwise subject to the liabilities of that section of
the Act but shall be subject to all other provisions of the Act (however, see
the Notes).
================================================================================
<PAGE>
CUSIP No. 464330109 G13 Page 2 of 5 Pages
- --------------------------------------------------------------------------------
(1) NAME OF REPORTING PERSON
Reliance Financial Services Corporation
S.S. or I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
I.R.S. Employer Identification No.: 51-0113548
- --------------------------------------------------------------------------------
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) | |
(b) | |
- --------------------------------------------------------------------------------
(3) SEC USE ONLY
- --------------------------------------------------------------------------------
(4) CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
- --------------------------------------------------------------------------------
(5) SOLE VOTING POWER
800,000 (See Note 1)
NUMBER OF SHARES ------------------------------------------------
BENEFICIALLY OWNED (6) SHARED VOTING POWER
BY EACH
REPORTING PERSON ------------------------------------------------
WITH (7) SOLE DISPOSITIVE POWER
800,000 (See Note 1)
------------------------------------------------
(8) SHARED DISPOSITIVE POWER
- --------------------------------------------------------------------------------
(9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
800,000 (See Note 1)
- --------------------------------------------------------------------------------
(10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
| |
- --------------------------------------------------------------------------------
(11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
2.6% (See Note 1)
- --------------------------------------------------------------------------------
(12) TYPE OF REPORTING PERSON*
HC
- --------------------------------------------------------------------------------
*SEE INSTRUCTION BEFORE FILLING OUT!
<PAGE>
CUSIP No. 464330109 G13 Page 3 of 5 Pages
Item 1. (a) Name of Issuer:
Isis Pharmaceuticals, Inc.
(b) Address of Issuer's Principal Executive Offices:
2292 Faraday Avenue, Carlsbad, California 92008
Item 2. (a) Name of Person Filing:
Reliance Financial Services Corporation
(b) Address of Principal Business Office or, if none, Residence:
Park Avenue Plaza, 55 East 52nd Street, New York, NY 10055
(c) Citizenship:
Delaware
(d) Title of Class of Securities:
Common Stock, Par Value $.001
(e) CUSIP Number:
464330109
Item 3. (g) |X| Parent Holding Company, in accordance with Section
240.13d-1(b)(1)(ii)(G)
Item 4. Ownership.
(a) Amount Beneficially Owned As of December 3l, l999:
800,000 (See Note 1)
(b) Percent of Class:
2.6% (See Note 1)
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote:
800,000 (See Note 1)
(ii) shared power to vote or to direct the vote:
-0- (See Note 1)
(iii) sole power to dispose or to direct the disposition of:
800,000 (See Note 1)
(iv) shared power to dispose or to direct the disposition of:
-0-
<PAGE>
CUSIP No. 464330109 G13 Page 4 of 5 Pages
Item 5. Ownership of Five Percent or Less of a Class.
If this statement is being filed to report the fact that as of the
date hereof the reporting person has ceased to be the beneficial
owner of more than five percent of the class of securities, check the
following /X/
Item 6. Ownership of More than Five Percent on Behalf of Another Person.
Not Applicable
Item 7. Identification and Classification of the Subsidiary which Acquired
the Security Being Reported on By the Parent Holding Company.
Reliance Insurance Company
Item 8. Identification and Classification of Members of the Group.
Not Applicable
Item 9. Notice of Dissolution of Group.
Not Applicable
<PAGE>
CUSIP No. 464330109 G13 Page 5 of 5 Pages
Item 10. Certification.
By signing below I certify that, to the best of my knowledge and belief,
the securities referred to above were acquired and are held in the ordinary
course of business and were not acquired and are not held for the purpose of or
with the effect of changing or influencing the control of the issuer of the
securities and were not acquired and are not held in connection with or as a
participant in any transaction having that purpose or effect.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief,
I certify that the information set forth in this statement is true, complete
and correct.
Date: February 11, 2000 as of December 31, 1999
RELIANCE FINANCIAL SERVICES CORPORATION
By: /s/ James E. Yacobucci
----------------------------------
James E. Yacobucci
Senior Vice President-Investments
<PAGE>
- -----------
Note 1. At December 31, 1999, Reliance Insurance Company ("RIC")
beneficially owned Common Stock Purchase Warrants entitling RIC to purchase
800,000 shares of Common Stock at a price of $25.00 per share. The Securities
benefically owned by RIC (assuming exercise of the Warrants) total 800,000
shares of Common Stock and represent 2.6% of the Securities outstanding.
